All News

The Summit provides a rare opportunity for professionals to dive deep into emerging healthcare technologies and treatment models.

Vin Gupta, MD, former Chief Medical Officer at Amazon Pharmacy and renowned US medical analyst, discusses pharmacists’ ability to reach communities and address social determinants of health.

Stanley V. Campbell, Jr., CEO of EagleForce Associates, Inc., and Yi Deng, PhD, Senior Vice President of Engineering at EagleForce, discuss the basics of AI and how it’s assisting with compliance.

The therapy achieved positive results during a phase 2b trial on the primary endpoint of percent change in Eczema Area and Severity Index (EASI) score.

Miranda Rochol, Senior Vice President of Provider Solutions at Prescryptive Health, discusses digital prescription solutions and how they are turning patients into consumers.

Brigid Groves, PharmD, MS, Vice President of Professional Affairs at APhA, discusses how the pharmacist’s role in immunization has adapted in recent history.

The therapy is currently under FDA review and has a PDUFA action date of May 22, 2025.

Angiotensin-converting enzyme inhibitors have been known to be more effective in decreasing the incidence of major adverse cardiac events for patients with diabetes.

President of 3 Axis Advisors and CEO of 46brooklyn Research joins Drug Topics to discuss nuances surrounding pharmacy benefit managers and the way they are perceived in the public eye.

A conversation with Douglas Hoey, RPh, MBA, CEO of NCPA, on the chain pharmacy’s announcement of a second Chapter 11 bankruptcy.

Guselkumab is the first and only IL-23 inhibitor to demonstrate robust data as a fully subcutaneous regimen.

Stanley V. Campbell, Jr., CEO of EagleForce Associates, Inc., and Yi Deng, PhD, Senior Vice President of Engineering at EagleForce, explore real-world examples of AI giving time back to pharmacists.

Patients often have anxiety about potential adverse effects, and experiencing adverse effects can affect patient adherence.

A phase 2 study found 95% of patients achieved a sustained virologic response at 12 weeks regardless of treatment adherence.

In this episode of the podcast, Natalie DiPietro Mager, PharmD, PhD, sits down with Jasmine Cutler, PharmD, CPh.

Selarsdi is interchangeable for all indications of ustekinumab, including treatment of psoriatic arthritis, plaque psoriasis, Crohn disease, and ulcerative colitis.

Stanley V. Campbell, Jr., CEO of EagleForce Associates, Inc., and Yi Deng, PhD, Senior Vice President of Engineering at EagleForce, discuss how AI is being used to benefit patients.

The use of electronic prescribing can also bridge the gap in clinical history, which can help pharmacists be aware of adverse drug reactions and medication interactions.

Among patients treated with buprenorphine, 25.4% experienced adverse pregnancy outcomes, compared to 30.8% in the untreated group.

Vaccination changes serotype distribution from vaccine-type serotypes to nonvaccine-type serotypes.

In this episode of the podcast, Shawn and Jesse discuss how every situation has a solution and the best way to find it.

Sarah Thomas and David Skomo of HealthDyne discuss some of the most useful innovations that have been helpful for pharmacies.

Casey Koch, PharmD, MBA, BCACP, clinical pharmacy coordinator at SelectHealth discusses how pharmacists can reduce patient burden.

Global virus and public health experts gathered to assess the need for an enhanced response to the bird flu spreading among humans and animals.

The investigators of a study also found that patient satisfaction with long-acting injectable antiretroviral therapy was equally as high when comparing home and clinic administration.

Shingle vaccination is recommended for adults 50 years and older and for adults 19 years and older who have a weakened immune system due to disease therapy.

Antonio Ciaccia, President of 3 Axis Advisors, CEO of 46brooklyn Research, and pharmacy benefits expert, discusses the commonly circulated misconceptions about PBMs.

As pharmacy schools continue to deal with recruitment challenges, the pharmacy workforce has its own set of challenges, including interest in nontraditional roles.

The nation’s largest PBM is placing Novo Nordisk’s premier weight-loss drug atop its formulary beginning July 1, 2025.

In the researchers’ review of data since 1990, they explored the global burden of infertility and the extent in which it is caused by either STIs or maternal sepsis.